• SPX
  • $5,859.85
  • 0.77 %
  • $44.82
  • DJI
  • $43,065.22
  • 0.47 %
  • $201.36
  • N225
  • $40,232.45
  • 1.58 %
  • $626.65
  • FTSE
  • $8,292.66
  • 0.47 %
  • $39.01
  • IXIC
  • $18,502.69
  • 0.87 %
  • $159.75
Aptevo Therapeutics Inc. (APVO) Stock Price, News & Analysis

Aptevo Therapeutics Inc. (APVO) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.14

-$0

(-1.31%)

Day's range
$0.14
Day's range
$0.15
50-day range
$0.138
Day's range
$0.483
  • Country: US
  • ISIN: US03835L2079
52 wk range
$0.14
Day's range
$16.59


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -27.43
  • Piotroski Score 3.00
  • Grade Overweight
  • Symbol (APVO)
  • Company Aptevo Therapeutics Inc.
  • Price $0.14
  • Changes Percentage (-1.31%)
  • Change -$0
  • Day Low $0.14
  • Day High $0.15
  • Year High $16.59

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/12/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$94.40
  • Trailing P/E Ratio -0.01
  • Forward P/E Ratio -0.01
  • P/E Growth -0.01
  • Net Income $-17,411,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.